New drug MTX325 enters first human tests for Parkinson's
NCT ID NCT07630545
First seen Jun 27, 2026 · Last updated Jul 30, 2026 · Updated 6 times
Summary
This early-stage study tests a new drug called MTX325 in healthy volunteers and people with mild to moderate Parkinson's disease. The main goals are to check safety, how the body processes the drug, and whether it reaches the brain. If successful, MTX325 might one day slow the progression of Parkinson's.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- MTX325
- What this could lead to
- If this works, MTX325 could become a treatment that slows or stops Parkinson's disease from getting worse.
- What could go wrong
- This is a very early Phase 1 trial with only 106 people, focused on safety. It may fail to show benefit or have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EARLY STAGE PARKINSON'S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cambridge Biomedical Research Centre, Cambridge
NOT_YET_RECRUITINGCambridge, United Kingdom
-
Centre Hospitalier Universitaire (CHU) de Toulouse, Toulouse
NOT_YET_RECRUITINGToulouse, France
-
Centre Hospitalier Universitaire de Lille, Institut Cœur Poumon
RECRUITINGLille, France
-
Doherty Clinical Trials
RECRUITINGMelbourne, Australia
-
Freeman Hospital, Newcastle Upon Tyne
RECRUITINGNewcastle, United Kingdom
-
Hôpital Henri-Mondor (Créteil, AP-HP), Paris
NOT_YET_RECRUITINGParis, France
-
Monash Health, Kingston Centre
NOT_YET_RECRUITINGMelbourne, Australia
-
Neuroclnx, Glasgow
NOT_YET_RECRUITINGGlasgow, United Kingdom
-
Parexel
COMPLETEDLondon, United Kingdom
-
Perceptive
COMPLETEDLondon, United Kingdom
-
Pitie-Salpetriere Hospital, Paris
NOT_YET_RECRUITINGParis, France
-
Royal Liverpool University Hospital
RECRUITINGLiverpool, United Kingdom
-
Salford Hospital (Manchester)
NOT_YET_RECRUITINGSalford, United Kingdom
-
Simbec-Orion
COMPLETEDMerthyr Tydfil, United Kingdom
-
Southampton General Hospital, Southampton
RECRUITINGSouthampton, United Kingdom
-
Technische Universitaet Dresden, Dresden
NOT_YET_RECRUITINGDresden, Germany
-
The Royal Adelaide Hospital
NOT_YET_RECRUITINGAdelaide, Australia
-
University Hospitals Plymouth NHS Trust, Derriford Hospital
RECRUITINGPlymouth, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- High-Resolution brain scans aim to unmask Tau's role in Parkinson's
- Can brain stimulation sharpen Decision-Making in Parkinson's?
- Can a new pill slow Parkinson's symptoms?
- Dancing away Parkinson's symptoms: tango therapy put to the test
- Can Stem-Cell implants restore movement in Parkinson's?
- Gentle bowing, calmer mind: music therapy put to the test for Parkinson's anxiety